Business Wire

Exclusive Networks Appoints Jesper Trolle as CEO

15.9.2020 10:00:00 EEST | Business Wire | Press release

Share

Exclusive Networks (‘Exclusive’) today announced the appointment of Jesper Trolle as CEO with immediate effect. Trolle joins Exclusive from ECS Arrow Electronics, where he is currently President of the Americas, and will be responsible for driving the next phase of growth at the company and upscaling the business. Trolle takes over from Olivier Breittmayer who becomes a non-executive Board member of Exclusive. The move is part of a planned succession strategy and Trolle will work alongside Breittmayer for the next three months to ensure a smooth transition.

Vastly experienced and recognised as an entrepreneurial business leader within the IT industry, Trolle has spent over 28 years working in the sector, initially within the reseller community, before moving into distribution. In 2001 he founded Next Denmark A/S which was acquired by DNS Denmark, which in turn was acquired by Arrow in 2005. Since then, Jesper has held a number of diverse positions in multiple locations within Arrow, seeing rapid success and progression, including stints in Germany running central and eastern Europe, and Paris, running north-west Europe. He took up the role as Arrow’s President Americas in 2017, based out of Denver, Colorado, where he has successfully grown a double-digit $bn business.

Speaking about the appointment, Breittmayer said, “Jesper was the standout choice following an intensive search and selection process these last six months or so. His cultural and international experience, obvious entrepreneurial DNA, knowledge of upscaling global businesses at pace and empathy with value-based distribution is impressive and refreshing. It is with confidence and a smile that we are getting such a capable person to take over the helm of the business we’ve grown by some 2,000% over the last 17 years.”

Talking of his appointment Trolle added, “Opportunities like this do not come around that often, but in distribution, Exclusive is at the top of the list if they do. I’m delighted to be joining such a successful company with a strong reputation for innovation and exceptional growth. Exclusive is renowned for its disruptive approach and relentless focus on value creation for its partners. When given the opportunity to become a part of the Exclusive family and next phase of its journey, it was an easy and fast decision to make.

“Olivier’s vision of creating the only specialist distributor on a global scale, focused on high performance cybersecurity infrastructure, was imaginative and disruptive – and that vision has become reality. Exclusive continues to buck market trends, growing at pace organically, expanding geographically and still disrupting. The only thing that hasn’t changed or been diluted is the obsession with value, services and specialism. This scale and specialist approach has never before been achieved. My job is clear: turn the global presence into a cybersecurity infrastructure powerhouse, at scale and speed, and it is a challenge I relish, feel qualified to do and very much look forward to,” concluded Trolle.

Michail Zekkos, Partner at Permira, and a member of Exclusive’s Board of Directors, commented, “Olivier is a pioneer and a true inspiration in modern day value-based distribution. It was a hard task to find his natural replacement, but in Jesper we feel we have done just that. He’s exceptionally talented and culturally very aligned to L’Esprit Exclusive. Olivier’s vision of building the Exclusive ‘Network’ of value-based distribution businesses, globally guided but locally delivered, was unique.

“The business has consistently outperformed market growth rates; expanded at breathtaking speed and delivered financial results that are exceptional for the sector. This is a great platform from which Jesper can continue the adventure and scale-out the business, and with his vision, multicultural background and experience of growth at scale we feel confident he is more than able to meet the challenge.

“Myself and the rest of the Exclusive family thank Olivier wholeheartedly for his indelible impact on the company, and welcome him onto the Board of Directors.”

Breittmayer added finally, “It’s not goodbye, it’s à plus tard.”

-ends-

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Exclusive Networks Contact:
Jon Bawden
Cohesive
+44 (0) 1291 626200
exclusivegroup@wearecohesive.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye